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Background: Myocardial ischaemia-reperfusion injury is a major cause of mortality and morbidity in 
the developed world. Many approaches have been investigated to counteract the pathological 
consequences associated with acute myocardial infarction (AMI) and cardiac remodelling. It is accepted 
that inflammation, and therefore activation of the complement pathway, is a crucial step in the 
pathogenesis of this injury and many attempts have been made to ameliorate the infarction and 
consequent dysfunction using anti-complement therapy, with mixed success. Recently, the alternative 
complement activation pathway involving the mannose binding lectin (MBL)-associated serine protease 
MASP-2 has been shown to me an important mediator of the inflammatory response in 
ischaemia/reperfusion injury in the heart. In this study, therefore, we aimed to investigate the feasibility 
of using specific and selective humanised monoclonal antibodies raised against MASP-2 in a murine 
model of AMI.  
Methods: Mice were injected with anti-MASP-2 antibody or control 18 hr prior to experimental 
infarction by ligation of the left anterior descending coronary artery for 30 min followed by 120 min 
reperfusion.  The developed infarct was measured and blood was collected for analysis of circulating 
MASP-2 levels.  
Results & Conclusions: We found that mice treated with anti-MASP-2 antibody had smaller infarcts 
than those treated with control antibody. We believe this may represent a valuable step forward in the 





What is already known about the subject: 
MASP-2 has been shown to be an important mediator of the inflammatory response following acute 
myocardial infarction. Previous studies using a MAPS-2 targeted mouse line with a germ-line global 
knockout of the MASP-2 gene showed that, in the context of acute injury, a significant reduction in post-
AMI injury was afforded. 
What does this study add: 
Since global knockout of a gene is not practical in a clinical setting we engineered a humanised anti-
MAPS-2 antibody. We demonstrate that this antibody can deplete circulating MASP-2 and, thus, creates 
an environment at the time of myocardial ischaemia and reperfusion where MASP-2 activity is low, thus 
affording a similar degree of cardiac protection.  
How much this impact on clinical practice: 
Whist the present study focusses on the role of MASP-2 pathway on acute myocardial protection 
following an ischaemic insult (experimental AMI) we would anticipate that this protective effect would 
further affect post-infarction remodelling in a clinical setting. Future studies will address the long-term 






Ischaemic heart disease is the leading causes of mortality in the developed world and contributes a 
significant burden of morbidity1 2. Acute myocardial infarction (AMI), caused by inadequate blood flow 
down one, or more, coronary arteries leads to necrosis and can initiate  chronic cardiac dysfunction and 
pathological cardiac remodelling3. It is widely accepted that the mortality from acute myocardial 
infarction is directly related to infarct size and inversely related to the amount of myocardial salvage 
achieved following reperfusion4 5. Likewise, detrimental myocardial remodelling, contractile 
dysfunction and electrophysiological instability are all greatly influenced by the volume of infarction3 6-
9. Although reperfusion following coronary artery occlusion is key to myocardial salvage, injury that 
continues following reperfusion, known as ‘reperfusion injury’ can be additive10-12. The critical 
observations confirming the presence of reperfusion injury are the now innumerable interventions that 
limit ultimate infarction when given at the moment of reperfusion13, since such interventions, by 
definition, are not present during ischaemia. Interventions that work at the moment on reperfusion 
include induced-hypothermia14, altered reperfusate composition15 16, staged, ramped or progressive 
reperfusion and17, perhaps most convincing of all, anti-inflammatory agents that limit complement 
activation18-20. 
It is now generally accepted that complement activation plays a key role in modulating myocardial 
ischaemia/reperfusion injury (MIRI) in animals and patients19 21, in keeping with its deposition in areas 
of infarction in the human heart22 23. This pathway is a fundamental component of the immune system, 
providing protection against invading microorganisms through both antibody-dependent and -
independent mechanisms and mediates many cellular and humoral interactions within the immune 
response, including chemotaxis, phagocytosis, cell adhesion, and B-cell differentiation24. Three 
different pathways initiate the complement cascade: the classical pathway, the alternative pathway and 
the lectin pathway (LP). The lectin pathway is initiated by the binding of multi-molecular activation 
complex to carbohydrate structures present on pathogens or glycocalyx pattern on mammalian cells. 
These complexes are composed of multimeric carbohydrate recognition subcomponents and the 
Mannose Binding Lectin (MBL)-associated serine proteases MASP-1, MASP-2 and MASP-325 26. This 
is a rapid first-line response toward pathogen-associated molecular patterns (PAMPs) or altered-self 
molecular motifs known as damage-associated molecular patterns (DAMPs) that are created during 
ischaemia/reperfusion injury27-29. Analyses of the sera and plasma of MASP-2 deficient mice 
demonstrates that MASP-2 is the only enzyme required to activate complement via the LP and neither 
MASP-1 nor MASP-3 are able to maintain LP activity in absence of MASP-230. We have previously 
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demonstrated the importance of the MASP-2 in MIRI using these knockout mice, where deficiency 
significantly reduces MIRI and tissue loss in an experimental model of myocardial infarction, whereas 
C4 deficient mice were not protected from MIRI31. These results indicate that long-term modulation of 
lectin pathway activity via MASP-2 deficiency indicates a potential opportunity in reducing morbidity 
(and mortality) in MIRI. However, for this opportunity to be realised the effect needs to be recapitulated 
by a therapeutic agent that transiently modulates the pathway. Such knowledge is a prerequisite in the 
clinical translation of anti-MASP-2 concept.  
The aim, therefore, of the current study was to determine whether selective anti-MASP-2 monoclonal 
antibody therapy, at a dose optimised to systemically ablate the lectin pathway in mice, will reduce 
infarct sizes in an established model of in vivo MIRI. We adopted to pre-treat experimental mice with 
depleting antibody therapy to ensure adequate effect of the dosing in accordance with some preliminary 
studies (data not shown) in order to assess the effect of MASP-2 depletion on AMI. 
Materials 
Unless otherwise stated all reagents, salts and stocks were from Sigma-Aldrich (Poole, UK). 8-0 nylon 
suture for ligation of the coronary artery were from Ethilon (Johnson & Johnson, UK). Anti-MASP-2 
monoclonal antibody (AbD04211) was isolated from Human Combinatorial Antibody Libraries 
(Serotec, AbD) using recombinant human and rat MASP-2A as antigens, as previously described31-33. 
To optimize the cDNA of the VH and VL regions for mammalian gene expression the genes were 
synthesized and the variable domain fragments were sub-cloned into the pMORPH2_h/m_Ig vector 
series for human/mouse IgG2a. These vectors carry the mouse gamma 2a constant region or the mouse 
lambda constant region, respectively. Eukaryotic HKB11 cells  were transfected with the IgG heavy and 
lambda light chain expression constructs by lipofection34.  
Culture supernatants were harvested 3 days after transfection and clarified by centrifugation.  Antibodies 
were purified from culture supernatants by single step protein A affinity chromatography, followed by 
buffer exchange and sterile filtration using proprietary reagents (Serotec, AbD). Antibody concentration 
was determined by spectrophotometry (OD280 using a calculated extinction coefficient of 13.7). The 
final purity of antibody preparations was assessed by SDS-PAGE and preparations were tested for 




All animal experiments were carried out in accordance with Home Office regulations as detailed in the 
Home Office Guidance on the Operation of Animals (Scientific Procedures) Act 1986. HMSO (London) 
which mirrors those found in the Guide for the Care and Use of Laboratory Animals published by the 
US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All experiments were 
carried out in a double-blinded manner using block randomization.  
MASP-2 depletion using Anti-MASP-2 monoclonal Antibody 
Dosing studies were carried out prior to carrying out the infarction arm of this study. Mice were 
administered with 0-2 mg/kg AbD04211 or vehicle and terminal blood samples were taken and used to 
determine C4d deposition as an indication of the efficacy of MSAP-2 depletion as described below. 
From these initial experiments a dosing regimen was established for the infarction study (see below). 
Infarction study 
Male C57BL/6 mice (n=46, average weight 31.8g) were dosed with 1.0 mg/kg anti-MASP-2 mIgG2a 
(AbD04211), isotype matched control antibody (Anti-hen lysozyme mouse IgG2a with human variable 
domains, #MOR3207, AbD Serotec, Germany) or vehicle (PBS) i.p. 12-18 h prior to surgery according 
to a block randomisation process with a block size of 6. All mice were subjected to 30 min of coronary 
artery occlusion followed by 120 min of reperfusion, and infarct sizes were evaluated. Mice were 
anesthetized with ketamine/metatomidine (100mg.kg-1 and 0.2mg.kg-1 respectively), intubated and 
ventilated with 100% oxygen (Minivent II, Hugo Sachs, Germany). A left mid thoracotomy was 
performed and the pericardium was opened and a pericardial cradle was formed to move the heart 
slightly anteriorly. The left anterior descending coronary artery (LAD) was located and a 8-0 
monofilament suture with a round needle was then passed under the LAD. Coronary artery occlusion 
was achieved using the hanging weight system as previously described35. Each end of the monofilament 
ligature was passed through a 2 mm long piece of a polythene PE-10 tube and attached to a mass of 1g 
over two horizontally mounted movable metal rods. By elevation of the rods the masses are suspended 
and the occlusion of the LAD is instituted with a defined and constant pressure. LAD occlusion was 
verified by paleness of the area at risk. Reperfusion is achieved by lowering the rods until the tension of 
the ligature is relieved and reperfusion was verified by the same three criteria used to verify occlusion. 
Mice were excluded from further analysis if all three criteria were not met. At the end of reperfusion, 
citrate-treated (10%, v/v, 110mM citrate, pH 8.3) blood samples were collected by direct cardiac 
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puncture and plasma obtained by centrifugation (1300 x g 15 min at 4C) and retained for 
pharmacodynamic studies at -70C.  
Finally, the LAD was re-occluded and 300µl Evans Blue (2% w/v in 0.9% v/w NaCl) injected into the 
jugular vein to delineate the area at risk. Hearts were rapidly excised, mounted in agarose and sliced in 
an ice bath (4C) into 750 µm sections from apex to base. All slices were incubated at 37° C for 20 min 
with 3% w/v 2,3,5-triphenyltetrazolium chloride (Sigma Aldrich, Poole, UK) dissolved in 0.1M 
Na2HPO4/NaH2PO4 buffer adjusted to pH 7.4. Slices were fixed overnight in 10% formaldehyde and 
then placed between two cover slips and digitally imaged using a high-resolution optical scanner (Epson, 
UK). Images were analysed using Sigma-Scan 5.0 software (SPSS, USA) and the size of infarcted area 
(pale), LV area at risk (red) and normally perfused LV zone (blue) were outlined in each section by 
identification of their appearance and borders. Areas were quantified on both sides of each slice and 
averaged. Infarct size was calculated as a percentage of risk zone (RZ) for each heart. Any mouse which 
did not survive the surgical protocol or have a measureable risk zone by Evans Blue staining was 
excluded from further analysis. One-way ANOVA for multiple comparisons was used to test for 
differences between treatment groups followed by a Bonferroni post-hoc test for pair wise comparisons. 
Significant differences were assumed when p<0.05. 
Complement Assay 
Lectin Pathway (LP) inhibitory activity of anti-MASP-2 mAb was assessed in a C4 deposition assay 
using dilute mouse serum. Appropriate dilutions of anti MASP-2 antibody was mixed with 0.5% normal 
mouse plasma in ‘CaMg-GVB’ buffer (gelatine veronal buffer containing 2.0 mM CaCl2 and 1.0 mM 
MgCl2) supplemented with 1.0 mg/mL of human C4 protein. 1µg of Mannan in coating buffer (15 mM 
Na2CO3, 35 mM NaHCO3, pH 9.6) was added to each well of an ELISA plate (Nunc MaxiSorb, Nunc 
International, Rochester, NY) and incubated overnight at 4°C. After a 1hr pre-incubation on ice, 
mixtures are transferred into Mannan-coated ELISA plates, and complement activation is initiated by 
transferring plates to a 37°C water bath. Following 1 hr incubation, reactions are stopped in an ice/water 
bath, followed by three washes with cold PBS-Tween 20 (0.05% Tween 20 in PBS) and two washes in 
PBS. To detect C4b deposition, wells are incubated with biotinylated anti-C4 antibody (diluted 1:3000 
in PBS containing 2.0 mg/ml BSA) for 1 hr at RT.  After washing wells 5 times with PBS, wells are 
incubated with 0.1 µg/ml of peroxidase-conjugated streptavidin (Pierce, diluted in PBS containing 2.0 
mg/ml BSA) for 1 hr at RT, washed with PBS and developed with TMB substrate and measured as 
absorbance at 450nm after addition of 20µl 100mM sulphuric acid to each well using a microplate 
absorbance spectrophotometer (Labsystems Multiscan Plus, Fischer Scientific, USA). 
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To assess the extent of LP depletion resulting from anti-MASP-2 or isotype control antibody 
administration, an ex vivo LP assay using minimally diluted mouse serum (90% final serum 
concentration) was employed. To prepare serum, mouse citrate plasma samples collected at various time 
points after test article administration were supplemented 10 mM with CaCl2 and incubated for 1 hr at 
37°C to allow fibrin clot formation.  The samples were then frozen at -70°C, thawed and centrifuged 
14,000 rpm for five min at 5°C in the refrigerated table-top centrifuge to remove the fibrin clot. Clear 
serum samples were then transferred to a polypropylene plate on ice. Serum from three control animals 
was pooled to generate reference LP activity values. To one aliquot of this serum pool anti-MASP-2 
blocking mAb was added (50 nM final concentration) while the other aliquot was supplemented with an 
equal volume of PBS. These samples were used to generate the 0% and 100% serum LP activity values, 
respectively. LP activation was initiated by transfer of 50 µl of mouse serum onto ELISA plates coated 
with Mannan followed by 90-min incubation at 0°C in an ice/water bath. To stop reactions samples were 
aspirated and ice cold EDTA-Tween-PBS buffer (20 mM EDTA, 0.5% Tween 20 in PBS) was added to 
wells.  Wells were washed three times with ice cold EDTA-Tween-PBS buffer followed by two washes 
with PBS at RT. To detect C4b deposition, wells were processed as described above. 
Results and Conclusions 
Out of 46 mice subject to experimental infarction, 41 completed the study and were evaluated. Five mice 
were excluded from analysis due to premature death (n=4), or because the inclusion criteria were not 
met (n=1). The exclusions were from all three groups; the anti MASP-2 (n=2) and isotype antibody (n-
1) and Vehicle (n=2) group. The outcome of C4 depletion through the use of the anti-MASP-2 mIgG2a 
(AbD04211) antibody is shown in Figure 1 (A-C). We found that a dose of 1.0mg/kg i.p. was effective 
in depleting C4d below the detection threshold of the assay at the first test point (6 hr) and was sustained 
for up to 180 hrs post-treatment (Figure 1C). The data from the infarction study are presented in Figure 
2. There was no difference in the risk zone (RZ) as a percentage of total left ventricle volume (%LV) 
between groups (P=0.8), indicating comparable magnitude of myocardial ischemia (Figure 1A). Infarcts, 
however, were significantly smaller in the AbD04211-treated group (15±1.0%) compared to control 
isotype (26.1±1.9%) and vehicle (22.4±1.8%) treated groups (p<0.005 and p<0.01, respectively (Figure 
2B)). A comparison of infarct sizes expressed as percentage of the risk zone, unsurprisingly, yielded 
similar results (Figure 2C & D). Infarcts were significantly smaller in animals treated with AbD04211 
(23.1±1.3%) compared to isotype control (38.5±2.1%) or vehicle (34.3±2%), and this effect was evident 
across a range of risk zones (Figure 2D). 
9 
 
Injury, resulting from myocardial ischaemia leads to a pro-inflammatory response which will, 
undoubtedly involve activation of the three complement activation pathways. Indeed, a recent clinical 
study has demonstrated that MASP-2 activation is involved in ischaemia-related necrotic myocardial 
injury in human subjects following MI36. Our data demonstrate that treatment with an anti MASP-2 
antibody blocking the lectin pathway of complement prior to ischaemia reduces the resultant infarction 
and increases myocardial salvage. One may suppose that anti MASP-2 therapy may also be useful to 
reduce infarct size, preserve contractile function and improve long term outcomes in MI patients 
undergoing PCI following occlusion of their coronary artery, although this is outside of the scope of this 
study but will be the focus of future studies in a more clinically-relevant model of post-AMI remodelling 
with concurrent treatment with M ASP-2-depleting therapy.  
We hypothesise, therefore, that the innate immune system, is responsible for continued myocardial 
injury during reperfusion following acute myocardial infarction. Ultimately, this injury would manifest 
in adverse post-infarction remodelling and poor contractile performance, clinical correlates of late onset 
cardiac failure7 9. If our hypothesis is correct, inhibiting the lectin pathway to complement activation in 
a more chronic manner following AMI may allow a window for therapeutic interventions that reduce 
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Figure 1 Dose-response of lectin pathway inhibition following administration of anti-MASP-2 
mAb (AbD04211) into C27BL/6 mice: A) AbD04211 (0.06, 0.2, 0.6 or 2.0 mg/kg) or vehicle (PBS) 
was injected (i.p.) into mice and terminal plasma samples collected 6 h after dosing.  LP was assessed 
in 90% serum using C4b deposition onto Mannan coated plates as readout. Each data point represents 
mean ± SD of three mice. C4 deposition in serum from mice dosed with vehicle (black filled circle), and 
C4 deposition using the same serum supplemented with 50nM of AbB04211 in vitro (black filled square) 
is shown for reference. Time-course of lectin pathway ablation and recovery following administration 
(i.p.) of 0.6 mg/kg (B) or 1 mg/kg (B) AbD04211 into mice. LP was assessed in 90% mouse serum using 
C4b deposition onto Mannan coated plates as readout. Each data point represents mean ± SD of three 
mice. Dashed lined shows baseline C4 deposition independent of  LP (naive mouse serum supplemented 
with 50 nM of AbD04211 in vitro). 
Figure 2 Infarct and risk zone assessments. Mice were subjected to 30 min ischaemia followed by 
120 min reperfusion in vivo. Risk zone (RZ), infarct size (INF) and left ventricle size (LV) were 
measured by Evans blue and tetrazolium staining. A) Risk zones determined in mice pre-treated with 
vehicle (PBS), isotype control Ab or AbB04211; B) infarct size as a percentage of LV mass and C) 
infarct size as a percentage of risk zone (RZ) in the three groups. C) Infarct (INF) vs. risk zone (RZ) in 
all the experimental mice. Data are presented as total area at risk (AAR) and infarct (INF) as a percentage 
of LV volume. Results are MEAN±SD of 13-15 independent experiments. **, P<0.01; *** P<0.005 as 
indicated. 
